ReviewFrontiers in pharmacology2022
Bibliometric analysis on exploitation of biogenic gold and silver nanoparticles in breast, ovarian and cervical cancer therapy.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Current trends and emerging patterns in the application of nanomaterials for ovarian cancer research: a bibliometric analysis.Frontiers in pharmacology · 2024Pooled it
- Current advancements and future research directions in the green synthesis and applications of nanoparticles.Discover nano · 2026Review
- Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.Oncotarget · 2026Review
- Applications of Nanoparticles in the Diagnosis and Treatment of Ovarian Cancer.Nanomaterials (Basel, Switzerland) · 2025Review
- Advances in hybrid hydrogel design for biomedical applications: innovations in drug delivery and tissue engineering for gynecological cancers.Cell biology and toxicology · 2025Review
- Advances in lysosomal escape mechanisms for gynecological cancer nano-therapeutics.Journal of pharmaceutical analysis · 2024Review
- Anticancer Action of Silver Nanoparticles in SKBR3 Breast Cancer Cells through Promotion of Oxidative Stress and Apoptosis.BioMed research international · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multifunctional nanoparticles are being formulated to overcome the side effects associated with anticancer drugs as well as conventional drug delivery systems. Cancer therapy has gained the advancement due to various pragmatic approaches with better treatment outcomes. The metal nanostructures such as gold and silver nanoparticles accessible
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.